Canaccord Genuity has reaffirmed its positive stance on Achieve Life Sciences (NASDAQ: ACHV), maintaining a 'buy' rating for the clinical-stage pharmaceutical company as it navigates regulatory hurdles in the United States. The reiteration comes after the US Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding Achieve's New Drug Application for cytisinicline, a treatment designed to help adults quit smoking.
A CRL is issued when the FDA determines it cannot approve a drug application in its current form, often requiring additional data or amendments. Achieve Life Sciences confirmed receipt of the CRL and stated it is reviewing the agency's feedback. The company has not yet provided a timeline for resubmission, though analysts at Canaccord believe the drug's underlying efficacy data remains strong.
For UK investors, the development is a reminder of the regulatory risks inherent in biotech stocks, particularly those reliant on US approvals. While Achieve Life Sciences is US-listed, its progress is watched by UK-based healthcare and specialist investment funds that hold positions in the sector. The broader biotech index has been volatile this year, with the NASDAQ Biotechnology Index falling roughly 3% since the start of July amid shifting interest rate expectations.
The FTSE 100 closed at 8,245.6 on Thursday, down 0.4%, as defensive sectors like pharmaceuticals weighed on the index. UK-listed smoking cessation and addiction treatment firms, such as those developing nicotine replacement therapies, may see indirect impact from Achieve's regulatory outcome, though no direct UK-listed peer has been named in connection with the CRL.
Canaccord's continued support suggests confidence in Achieve's ability to resolve the FDA's concerns, but the stock remains under a cloud of uncertainty. Analysts caution that delays in approval could affect the company's cash runway and near-term share price. Achieve reported cash reserves of approximately $45 million as of its last quarterly filing, which may fund operations into mid-2027 if the review process extends.